Skip to main page content
Accesskeys

dbSNP Short Genetic Variations

Reference SNP (rs) Report

This page reports data for a single dbSNP Reference SNP variation (RefSNP or rs) from the new redesigned dbSNP build.
Top of the page reports a concise summary for the rs, with more specific details included in the corresponding tabs below.
All alleles are reported in the Forward orientation. Use the Genomic View to inspect the nucleotides flanking the variant, and its neighbors.
For more information see Help documentation.

rs12979860

Current Build 152

Released October 2, 2018

Organism
Homo sapiens
Position
chr19:39248147 (GRCh38.p12) Help

The anchor position for this RefSNP. Includes all nucleotides potentially affected by this change, thus it can differ from HGVS, which is right-shifted. See here for details.

Alleles
C>T
Variation Type
SNV Single Nucleotide Variation
Frequency
T=0.39067 (49056/125568, TOPMED)
T=0.3775 (11659/30884, GnomAD)
T=0.356 (1782/5008, 1000G) (+ 2 more)
T=0.300 (1157/3854, ALSPAC)
T=0.307 (1140/3708, TWINSUK)
Clinical Significance
Reported in ClinVar
Gene : Consequence
IFNL4 : Intron Variant
Publications
597 citations
Genomic View
See rs on genome
Help

Variant Details tab shows known variant placements on genomic sequences: chromosomes (NC_), RefSeqGene, pseudogenes or genomic regions (NG_), and in a separate table: on transcripts (NM_) and protein sequences (NP_). The corresponding transcript and protein locations are listed in adjacent lines, along with molecular consequences from Sequence Ontology. When no protein placement is available, only the transcript is listed. Column "Codon[Amino acid]" shows the actual base change in the format of "Reference > Alternate" allele, including the nucleotide codon change in transcripts, and the amino acid change in proteins, respectively, allowing for known ribosomal slippage sites. To view nucleotides adjacent to the variant use the Genomic View at the bottom of the page - zoom into the sequence until the nucleotides around the variant become visible.

Genomic Placements
Sequence name Change
GRCh38.p12 chr 19 NC_000019.10:g.39248147C>T
GRCh37.p13 chr 19 NC_000019.9:g.39738787C>T
IFNL4 RefSeqGene NG_055295.1:g.5710G>A
IFNL3 RefSeqGene NG_042193.1:g.1825G>A
Gene: IFNL4, interferon lambda 4 (gene/pseudogene) (minus strand)
Molecule type Change Amino acid[Codon] SO Term
IFNL4 transcript variant 2 NR_074079.1:n. N/A Intron Variant
Help

Clinical Significance tab shows a list of clinical significance entries from ClinVar associated with the variation, per allele. Click on the RCV accession (i.e. RCV000001615.2) or Allele ID (i.e. 12274) to access full ClinVar report.

Allele: T (allele ID: 227801 )
ClinVar Accession Disease Names Clinical Significance
RCV000211184.1 peginterferon alfa-2a, peginterferon alfa-2b, ribavirin, and telaprevir response - Efficacy Drug-Response
RCV000211399.1 peginterferon alfa-2a, peginterferon alfa-2b, and ribavirin response - Efficacy Drug-Response
RCV000417146.1 peginterferon alfa-2b response - Efficacy Drug-Response
RCV000417163.1 ribavirin response - Efficacy Drug-Response
RCV000417179.1 boceprevir response - Efficacy Drug-Response
RCV000614473.1 not specified Benign
Help

Frequency tab displays a table of the reference and alternate allele frequencies reported by various studies and populations. Table lines, where Population="Global" refer to the entire study population, whereas lines, where Group="Sub", refer to a study-specific population subgroupings (i.e. AFR, CAU, etc.), if available. Frequency for the alternate allele (Alt Allele) is a ratio of samples observed-to-total, where the numerator (observed samples) is the number of chromosomes in the study with the minor allele present (found in "Sample size", where Group="Sub"), and the denominator (total samples) is the total number of all chromosomes in the study for the variant (found in "Sample size", where Group="Study-wide" and Population="Global").

Download
Study Population Group Sample Size Ref Allele Alt Allele
TopMed Global Study-wide 125568 C=0.60933 T=0.39067
gnomAD - Genomes Global Study-wide 30884 C=0.6225 T=0.3775
gnomAD - Genomes European Sub 18430 C=0.6933 T=0.3067
gnomAD - Genomes African Sub 8720 C=0.405 T=0.595
gnomAD - Genomes East Asian Sub 1618 C=0.944 T=0.056
gnomAD - Genomes Other Sub 978 C=0.70 T=0.30
gnomAD - Genomes American Sub 836 C=0.62 T=0.38
gnomAD - Genomes Ashkenazi Jewish Sub 302 C=0.61 T=0.39
1000Genomes Global Study-wide 5008 C=0.644 T=0.356
1000Genomes African Sub 1322 C=0.331 T=0.669
1000Genomes East Asian Sub 1008 C=0.920 T=0.080
1000Genomes Europe Sub 1006 C=0.691 T=0.309
1000Genomes South Asian Sub 978 C=0.77 T=0.23
1000Genomes American Sub 694 C=0.60 T=0.40
The Avon Longitudinal Study of Parents and Children PARENT AND CHILD COHORT Study-wide 3854 C=0.700 T=0.300
UK 10K study - Twins TWIN COHORT Study-wide 3708 C=0.693 T=0.307
Help

Aliases tab displays HGVS names representing the variant placements and allele changes on genomic, transcript and protein sequences, per allele. HGVS name is an expression for reporting sequence accession and version, sequence type, position, and allele change. The column "Note" can have two values: "diff" means that there is a difference between the reference allele (variation interval) at the placement reported in HGVS name and the reference alleles reported in other HGVS names, and "rev" means that the sequence of this variation interval at the placement reported in HGVS name is in reverse orientation to the sequence(s) of this variation in other HGVS names not labeled as "rev".

Placement C= T Note
GRCh38.p12 chr 19 NC_000019.10:g.39248147C= NC_000019.10:g.39248147C>T
GRCh37.p13 chr 19 NC_000019.9:g.39738787C= NC_000019.9:g.39738787C>T
IFNL4 RefSeqGene NG_055295.1:g.5710G= NG_055295.1:g.5710G>A
IFNL3 RefSeqGene NG_042193.1:g.1825G= NG_042193.1:g.1825G>A
Help

Submissions tab displays variations originally submitted to dbSNP, now supporting this RefSNP cluster (rs). We display Submitter handle, Submission identifier, Date and Build number, when the submission appeared for the first time. Direct submissions to dbSNP have Submission ID in the form of an ss-prefixed number (ss#). Other supporting variations are listed in the table without ss#.

72 SubSNP, 5 Frequency, 6 ClinVar submissions
No Submitter Submission ID Date (Build)
1 SSAHASNP ss21535512 Apr 05, 2004 (121)
2 ABI ss41007958 Mar 14, 2006 (126)
3 ILLUMINA ss75310850 Dec 06, 2007 (129)
4 HGSV ss78402638 Dec 06, 2007 (129)
5 BCMHGSC_JDW ss90972021 Mar 24, 2008 (129)
6 HUMANGENOME_JCVI ss96306171 Feb 03, 2009 (130)
7 1000GENOMES ss111372502 Jan 25, 2009 (130)
8 1000GENOMES ss115127572 Jan 25, 2009 (130)
9 ILLUMINA-UK ss117704479 Feb 14, 2009 (130)
10 KRIBB_YJKIM ss119820267 Dec 01, 2009 (131)
11 ILLUMINA ss123417708 Dec 01, 2009 (131)
12 ENSEMBL ss137673719 Dec 01, 2009 (131)
13 ILLUMINA ss153304285 Dec 01, 2009 (131)
14 ILLUMINA ss160310582 Dec 01, 2009 (131)
15 COMPLETE_GENOMICS ss169725740 Jul 04, 2010 (132)
16 ILLUMINA ss170267528 Jul 04, 2010 (132)
17 ILLUMINA ss172294859 Jul 04, 2010 (132)
18 BCM-HGSC-SUB ss208491878 Jul 04, 2010 (132)
19 1000GENOMES ss228138270 Jul 14, 2010 (132)
20 1000GENOMES ss237676123 Jul 15, 2010 (132)
21 1000GENOMES ss243882605 Jul 15, 2010 (132)
22 GMI ss283208441 May 04, 2012 (137)
23 PJP ss292249552 May 09, 2011 (134)
24 ILLUMINA ss479852468 May 04, 2012 (137)
25 ILLUMINA ss479860037 May 04, 2012 (137)
26 ILLUMINA ss480459004 Sep 08, 2015 (146)
27 ILLUMINA ss484724746 May 04, 2012 (137)
28 EXOME_CHIP ss491546752 May 04, 2012 (137)
29 TISHKOFF ss565980822 Apr 25, 2013 (138)
30 SSMP ss661845347 Apr 25, 2013 (138)
31 ILLUMINA ss782809075 Sep 08, 2015 (146)
32 ILLUMINA ss825673338 Apr 01, 2015 (144)
33 ILLUMINA ss832062221 Sep 08, 2015 (146)
34 EVA-GONL ss994296026 Aug 21, 2014 (142)
35 JMKIDD_LAB ss1081901677 Aug 21, 2014 (142)
36 1000GENOMES ss1363150415 Aug 21, 2014 (142)
37 DDI ss1428402826 Apr 01, 2015 (144)
38 EVA_UK10K_ALSPAC ss1637961936 Apr 01, 2015 (144)
39 EVA_UK10K_TWINSUK ss1680955969 Apr 01, 2015 (144)
40 EVA_DECODE ss1698349552 Apr 01, 2015 (144)
41 EVA_MGP ss1711512534 Apr 01, 2015 (144)
42 EVA_SVP ss1713662429 Apr 01, 2015 (144)
43 ILLUMINA ss1752284784 Sep 08, 2015 (146)
44 HAMMER_LAB ss1809306058 Sep 08, 2015 (146)
45 WEILL_CORNELL_DGM ss1937789874 Feb 12, 2016 (147)
46 ILLUMINA ss1959863218 Feb 12, 2016 (147)
47 JJLAB ss2029674034 Sep 14, 2016 (149)
48 USC_VALOUEV ss2158214106 Dec 20, 2016 (150)
49 TOPMED ss2391450936 Dec 20, 2016 (150)
50 ILLUMINA ss2633539536 Nov 08, 2017 (151)
51 GRF ss2702824666 Nov 08, 2017 (151)
52 GNOMAD ss2962824156 Nov 08, 2017 (151)
53 AFFY ss2985141451 Nov 08, 2017 (151)
54 AFFY ss2985771909 Nov 08, 2017 (151)
55 SWEGEN ss3017465689 Nov 08, 2017 (151)
56 ILLUMINA ss3021904980 Nov 08, 2017 (151)
57 BIOINF_KMB_FNS_UNIBA ss3028669069 Nov 08, 2017 (151)
58 TOPMED ss3293195516 Nov 08, 2017 (151)
59 CSHL ss3352301434 Nov 08, 2017 (151)
60 ILLUMINA ss3625741612 Oct 12, 2018 (152)
61 ILLUMINA ss3633890578 Oct 12, 2018 (152)
62 ILLUMINA ss3634735054 Oct 12, 2018 (152)
63 ILLUMINA ss3635577383 Oct 12, 2018 (152)
64 ILLUMINA ss3636422599 Oct 12, 2018 (152)
65 ILLUMINA ss3637329121 Oct 12, 2018 (152)
66 ILLUMINA ss3638226966 Oct 12, 2018 (152)
67 ILLUMINA ss3640442362 Oct 12, 2018 (152)
68 ILLUMINA ss3643199921 Oct 12, 2018 (152)
69 ILLUMINA ss3644723818 Oct 12, 2018 (152)
70 URBANLAB ss3650917419 Oct 12, 2018 (152)
71 ILLUMINA ss3652330913 Oct 12, 2018 (152)
72 ILLUMINA ss3653913973 Oct 12, 2018 (152)
73 1000Genomes NC_000019.9 - 39738787 Oct 12, 2018 (152)
74 The Avon Longitudinal Study of Parents and Children NC_000019.9 - 39738787 Oct 12, 2018 (152)
75 gnomAD - Genomes NC_000019.9 - 39738787 Oct 12, 2018 (152)
76 TopMed NC_000019.10 - 39248147 Oct 12, 2018 (152)
77 UK 10K study - Twins NC_000019.9 - 39738787 Oct 12, 2018 (152)
78 ClinVar RCV000211184.1 Oct 12, 2018 (152)
79 ClinVar RCV000211399.1 Oct 12, 2018 (152)
80 ClinVar RCV000417146.1 Oct 12, 2018 (152)
81 ClinVar RCV000417163.1 Oct 12, 2018 (152)
82 ClinVar RCV000417179.1 Oct 12, 2018 (152)
83 ClinVar RCV000614473.1 Oct 12, 2018 (152)
Help

History tab displays RefSNPs (Associated ID) from previous builds (Build) that now support the current RefSNP, and the dates, when the history was updated for each Associated ID (History Updated).

Added to this RefSNP Cluster:
Submission ids Observation SPDI Canonical SPDI Source RSIDs
ss78402638, ss90972021, ss111372502, ss115127572, ss117704479, ss169725740, ss208491878, ss283208441, ss292249552, ss479852468, ss825673338, ss1698349552, ss1713662429, ss3643199921 NC_000019.8:44430626:C= NC_000019.10:39248146:C= (self)
76557276, 42403139, 96525686, 42403139, ss228138270, ss237676123, ss243882605, ss479860037, ss480459004, ss484724746, ss491546752, ss565980822, ss661845347, ss782809075, ss832062221, ss994296026, ss1081901677, ss1363150415, ss1428402826, ss1637961936, ss1680955969, ss1711512534, ss1752284784, ss1809306058, ss1937789874, ss1959863218, ss2029674034, ss2158214106, ss2391450936, ss2633539536, ss2702824666, ss2962824156, ss2985141451, ss2985771909, ss3017465689, ss3021904980, ss3352301434, ss3625741612, ss3633890578, ss3634735054, ss3635577383, ss3636422599, ss3637329121, ss3638226966, ss3640442362, ss3644723818, ss3652330913, ss3653913973 NC_000019.9:39738786:C= NC_000019.10:39248146:C= (self)
181075160, ss3028669069, ss3293195516, ss3650917419 NC_000019.10:39248146:C= NC_000019.10:39248146:C= (self)
ss21535512 NT_011109.15:12007004:C= NC_000019.10:39248146:C= (self)
ss41007958, ss75310850, ss96306171, ss119820267, ss123417708, ss137673719, ss153304285, ss160310582, ss170267528, ss172294859 NT_011109.16:12007004:C= NC_000019.10:39248146:C= (self)
ss78402638, ss90972021, ss111372502, ss115127572, ss117704479, ss169725740, ss208491878, ss283208441, ss292249552, ss479852468, ss825673338, ss1698349552, ss1713662429, ss3643199921 NC_000019.8:44430626:C>T NC_000019.10:39248146:C>T (self)
76557276, 42403139, 96525686, 42403139, ss228138270, ss237676123, ss243882605, ss479860037, ss480459004, ss484724746, ss491546752, ss565980822, ss661845347, ss782809075, ss832062221, ss994296026, ss1081901677, ss1363150415, ss1428402826, ss1637961936, ss1680955969, ss1711512534, ss1752284784, ss1809306058, ss1937789874, ss1959863218, ss2029674034, ss2158214106, ss2391450936, ss2633539536, ss2702824666, ss2962824156, ss2985141451, ss2985771909, ss3017465689, ss3021904980, ss3352301434, ss3625741612, ss3633890578, ss3634735054, ss3635577383, ss3636422599, ss3637329121, ss3638226966, ss3640442362, ss3644723818, ss3652330913, ss3653913973 NC_000019.9:39738786:C>T NC_000019.10:39248146:C>T (self)
RCV000211184.1, RCV000211399.1, RCV000417146.1, RCV000417163.1, RCV000417179.1, RCV000614473.1, 181075160, ss3028669069, ss3293195516, ss3650917419 NC_000019.10:39248146:C>T NC_000019.10:39248146:C>T (self)
ss21535512 NT_011109.15:12007004:C>T NC_000019.10:39248146:C>T (self)
ss41007958, ss75310850, ss96306171, ss119820267, ss123417708, ss137673719, ss153304285, ss160310582, ss170267528, ss172294859 NT_011109.16:12007004:C>T NC_000019.10:39248146:C>T (self)
Help

Publications tab displays PubMed articles citing the variation as a listing of PMID, Title, Author, Year, Journal, ordered by Year, descending.

597 citations for rs12979860
PMID Title Author Year Journal
19684573 Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Ge D et al. 2009 Nature
19759533 Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Thomas DL et al. 2009 Nature
20176026 Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. McCarthy JJ et al. 2010 Gastroenterology
20184973 Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle. Thio CL et al. 2010 Gastroenterology
20235331 Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Li JH et al. 2010 Hepatology (Baltimore, Md.)
20389235 Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. Rallón NI et al. 2010 AIDS (London, England)
20399780 Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Thompson AJ et al. 2010 Gastroenterology
20547162 Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Thompson AJ et al. 2010 Gastroenterology
20578254 Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Montes-Cano MA et al. 2010 Hepatology (Baltimore, Md.)
20621700 An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Mangia A et al. 2010 Gastroenterology
20633102 Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Asselah T et al. 2010 Liver international
20637200 A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Tillmann HL et al. 2010 Gastroenterology
20648473 Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Akuta N et al. 2010 Hepatology (Baltimore, Md.)
20659305 A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. Galmozzi E et al. 2011 Journal of viral hepatitis
20728570 Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Stättermayer AF et al. 2011 Clinical gastroenterology and hepatology
20729732 Host genetic basis for hepatitis C virus clearance: a role for blood collection centers. Selvarajah S et al. 2010 Current opinion in hematology
20803561 Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Grebely J et al. 2010 Hepatology (Baltimore, Md.)
20804372 Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Pineda JA et al. 2010 Clinical infectious diseases
20889274 IL28B polymorphisms and chronic hepatitis C. Chevaliez S et al. 2010 Gastroenterologie clinique et biologique
20931559 IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Urban TJ et al. 2010 Hepatology (Baltimore, Md.)
20950615 IL28B and the control of hepatitis C virus infection. Balagopal A et al. 2010 Gastroenterology
20964522 Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Medrano J et al. 2010 Clinical infectious diseases
20977343 IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. Martin MP et al. 2010 The Journal of infectious diseases
21068134 HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Hayes CN et al. 2011 Gut
21070502 Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort. Clausen LN et al. 2011 Journal of viral hepatitis
21080244 The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection. Pearlman BL et al. 2011 Current gastroenterology reports
21112657 Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. Sarrazin C et al. 2011 Journal of hepatology
21112660 Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. Kawaoka T et al. 2011 Journal of hepatology
21145807 Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. Scherzer TM et al. 2011 Journal of hepatology
21145813 Interferon-lambda serum levels in hepatitis C. Langhans B et al. 2011 Journal of hepatology
21146242 IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. Fabris C et al. 2011 Journal of hepatology
21147186 Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. Lange CM et al. 2011 Journal of hepatology
21147189 IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. Zhang L et al. 2011 Journal of hepatology
21157362 Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. de Araujo ES et al. 2011 Journal of acquired immune deficiency syndromes (1999)
21228123 IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations. Ochi H et al. 2011 The Journal of general virology
21246582 Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Suzuki F et al. 2011 Hepatology (Baltimore, Md.)
21254158 Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Darling JM et al. 2011 Hepatology (Baltimore, Md.)
21254179 Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Charlton MR et al. 2011 Hepatology (Baltimore, Md.)
21274371 Peginterferon and ribavirin treatment for hepatitis C virus infection. Tsubota A et al. 2011 World journal of gastroenterology
21303914 Interferon lambdas: the next cytokine storm. Kelly C et al. 2011 Gut
21345258 Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics. Tavis JE et al. 2011 Genome medicine
21346780 IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection. Chen JY et al. 2011 Genes and immunity
21354446 IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. Bochud PY et al. 2011 Journal of hepatology
21360716 Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. di Iulio J et al. 2011 Hepatology (Baltimore, Md.)
21374656 IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Moghaddam A et al. 2011 Hepatology (Baltimore, Md.)
21375685 Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. Neukam K et al. 2011 HIV medicine
21376050 Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Freedman ND et al. 2011 Gastroenterology
21378537 Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. Labarga P et al. 2011 AIDS (London, England)
21389156 The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. Ito K et al. 2011 Journal of clinical microbiology
21390311 Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. Lagging M et al. 2011 PloS one
21397726 Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Reiberger T et al. 2011 Clinical gastroenterology and hepatology
21413051 Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Ruiz-Extremera A et al. 2011 Hepatology (Baltimore, Md.)
21447862 Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Liao XW et al. 2011 Antiviral therapy
21466653 Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Coto-Llerena M et al. 2011 American journal of transplantation
21479134 IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. Lin CY et al. 2011 PloS one
21488075 Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Trépo E et al. 2011 Hepatology (Baltimore, Md.)
21505315 IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. Rallón NI et al. 2011 AIDS (London, England)
21537116 Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse. Labarga P et al. 2011 AIDS (London, England)
21549150 Real-time polymerase chain reaction assay based on high-resolution melting analysis for the determination of the rs12979860 polymorphism involved in hepatitis C treatment response. Kovanda A et al. 2011 Journal of virological methods
21572301 Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. Pineda JA et al. 2011 AIDS (London, England)
21592993 Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. Barreiro P et al. 2011 The Journal of infectious diseases
21600205 A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Knapp S et al. 2011 Gastroenterology
21606533 Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. Lindh M et al. 2011 The Journal of infectious diseases
21613433 Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients. Fonseca-Coronado S et al. 2011 Journal of clinical microbiology
21626525 Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Mangia A et al. 2011 Hepatology (Baltimore, Md.)
21628662 IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. Chayama K et al. 2011 The Journal of infectious diseases
21647799 Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. Falleti E et al. 2011 Journal of clinical immunology
21670772 Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. de Rueda PM et al. 2011 The American journal of gastroenterology
21692944 IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. Lindh M et al. 2011 Journal of viral hepatitis
21694902 New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents. Quer J et al. 2010 Infection and drug resistance
21703198 Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. Tillmann HL et al. 2011 Journal of hepatology
21703201 The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation. Nattermann J et al. 2011 Journal of hepatology
21704279 Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. Melis R et al. 2011 The Journal of molecular diagnostics
21721028 Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Marabita F et al. 2011 Hepatology (Baltimore, Md.)
21722179 Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data. Ladero JM et al. 2012 Journal of gastroenterology and hepatology
21726252 IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin. Giannini EG et al. 2011 Alimentary pharmacology & therapeutics
21739451 Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. Abe H et al. 2011 Journal of medical virology
21742841 IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection. Scott J et al. 2011 The Journal of infectious diseases
21790472 IL28B polymorphism associated with spontaneous clearance of hepatitis C infection in a Southern Brazilian HIV type 1 population. Lunge VR et al. 2012 AIDS research and human retroviruses
21813376 Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rs12979860 polymorphism of the IL28B gene. Lutz P et al. 2011 European journal of medical research
21820962 Interferon-lambda and therapy for chronic hepatitis C virus infection. Donnelly RP et al. 2011 Trends in immunology
21854194 Distribution of polymorphisms in cytochrome P450 2B6, histocompatibility complex P5, chemokine coreceptor 5, and interleukin 28B genes in inhabitants from the central area of Argentina. Galván CA et al. 2012 Genetic testing and molecular biomarkers
21884576 Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Smith KR et al. 2011 Genome medicine
21889215 IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis. Malhotra S et al. 2011 Journal of neuroimmunology
21889467 Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. Coto-Llerena M et al. 2012 Journal of hepatology
21898478 Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Asahina Y et al. 2012 Hepatology (Baltimore, Md.)
21900787 A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. Halfon P et al. 2011 European journal of gastroenterology & hepatology
21903134 Interleukin 28B genotype determination using DNA from different sources: A simple and reliable tool for the epidemiological and clinical characterization of hepatitis C. Cariani E et al. 2011 Journal of virological methods
21907615 Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. Lyoo K et al. 2011 Journal of clinical virology
21911885 Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ridruejo E et al. 2011 Annals of hepatology
21918436 Host genetics. Macías J et al. 2011 Current opinion in HIV and AIDS
21931540 IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. Suppiah V et al. 2011 PLoS medicine
21932410 Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias? Beinhardt S et al. 2012 Hepatology (Baltimore, Md.)
21932415 Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. De Nicola S et al. 2012 Hepatology (Baltimore, Md.)
21933876 Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort. Kurbanov F et al. 2011 The Journal of infectious diseases
21946415
21951981 IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. Asselah T et al. 2012 Journal of hepatology
21971821 Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. Neukam K et al. 2012 European journal of clinical microbiology & infectious diseases
21974859 Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin. Arends JE et al. 2011 International journal of antimicrobial agents
21983945 Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Golden-Mason L et al. 2011 Hepatology (Baltimore, Md.)
21984735 High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. Chattergoon MA et al. 2011 The Journal of infectious diseases
21987611 IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients. Venegas M et al. 2011 World journal of gastroenterology
21993426 Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C. Lopez-Rodriguez R et al. 2011 Clinical pharmacology and therapeutics
22003405 IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. Dayyeh BK et al. 2011 PloS one
22006276 Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. Scherzer TM et al. 2011 Hepatology (Baltimore, Md.)
22013224 IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association. Shebl FM et al. 2011 The Journal of infectious diseases
22027585 Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. Howell CD et al. 2012 Journal of hepatology
22046316 Genetic variation of the IL-28B promoter affecting gene expression. Sugiyama M et al. 2011 PloS one
22087138 Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Li S et al. 2011 Hepatitis monthly
22098416 IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population. Cavalcante LN et al. 2012 Liver international
22108195 Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Sonneveld MJ et al. 2012 Gastroenterology
22110669 Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. van den Berg CH et al. 2011 PloS one
22118055 Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy. Lötsch J et al. 2011 Pharmacogenomics
22158703 Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. Naggie S et al. 2012 The Journal of infectious diseases
22162829 Evolutionary genetic dissection of human interferons. Manry J et al. 2011 The Journal of experimental medicine
22173157 Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. Neukam K et al. 2012 Journal of hepatology
22180419 IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Di Marco V et al. 2012 Haematologica
22192885 Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Beinhardt S et al. 2012 Gastroenterology
22212648 Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients. Tsubota A et al. 2012 Liver international
22222052 Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes. Berenguer M et al. 2012 Journal of clinical virology
22234804 Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Liu L et al. 2012 Hepatology (Baltimore, Md.)
22234924 Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Fischer J et al. 2012 Hepatology (Baltimore, Md.)
22239156 IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Peng LJ et al. 2012 Tissue antigens
22248659 Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Chu TW et al. 2012 Gastroenterology
22253715 Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. Rembeck K et al. 2012 PloS one
22253847 Sequence analysis of the IL28A/IL28B inverted gene duplication that contains polymorphisms associated with treatment response in hepatitis C patients. Reynolds JM et al. 2012 PloS one
22275900 Pharmacogenomics: what is next? di Iulio J et al. 2011 Frontiers in pharmacology
22285807 Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. McGilvray I et al. 2012 Gastroenterology
22294646 Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. Rallón NI et al. 2012 The Journal of antimicrobial chemotherapy
22295096 Genetic variations in IL28B and allergic disease in children. Gaudieri S et al. 2012 PloS one
22298465 Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. Graziadei IW et al. 2012 Liver transplantation
22300408 Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Veldt BJ et al. 2012 American journal of transplantation
22310928 Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Ren S et al. 2012 Cancer immunology, immunotherapy
22314430 IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. Petta S et al. 2012 Journal of hepatology
22324878 Short communication: Does interleukin-28B single nucleotide polymorphisms influence the natural history of hepatitis B? Martín-Carbonero L et al. 2012 AIDS research and human retroviruses
22328925 Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients. de Castellarnau M et al. 2012 PloS one
22329371 IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. Rao HY et al. 2012 Journal of viral hepatitis
22329378 Discordant results using T-ARMS-PCR and sequencing for the evaluation of rs12979860 IL28B genotype. de Sa Filho DJ et al. 2012 Journal of viral hepatitis
22329379
22331604 Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Naggie S et al. 2012 Hepatology (Baltimore, Md.)
22331649 HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Uccellini L et al. 2012 Hepatology (Baltimore, Md.)
22345656 IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Antaki N et al. 2012 Gut
22362153 Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b. Rallón NI et al. 2012 Journal of acquired immune deficiency syndromes (1999)
22368681 The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C. Sporea I et al. 2011 Hepatitis monthly
22374338 Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis. Scagnolari C et al. 2012 Virus research
22387386 Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay. Li W et al. 2012 Antiviral research
22411462 Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Eurich D et al. 2012 Transplantation
22414761 Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity. Sheridan DA et al. 2012 Journal of hepatology
22431022 The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. Fabris C et al. 2012 Journal of medical virology
22438096 Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. Kobayashi M et al. 2012 Journal of gastroenterology
22460962 Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. Treviño A et al. 2012 Clinical infectious diseases
22473858 IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Lampertico P et al. 2013 Hepatology (Baltimore, Md.)
22495472 Recipient interleukin-28B Rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used. Bitetto D et al. 2012 Transplantation
22497812 Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. Clark PJ et al. 2012 Journal of viral hepatitis
22505587 Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Petta S et al. 2012 Antiviral therapy
22509814 Frequency of IL28B rs12979860 single-nucleotide polymorphism alleles in newborn infants and in patients with chronic hepatitis C in Morocco. Tajir M et al. 2012 Genetic testing and molecular biomarkers
22521237 Closed tube method for rapid screening of IL28B polymorphisms involved in response to hepatitis C treatment. Habalová V et al. 2012 Molecular and cellular probes
22530607 Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Valenti L et al. 2012 Alimentary pharmacology & therapeutics
22537149 Development of new IL28B genotyping method using Invader Plus assay. Kani S et al. 2012 Microbiology and immunology
22543885 The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Clark PJ et al. 2012 Digestive diseases and sciences
22545770 IL28B CC genotype is associated with higher all-cause mortality in antiretroviral-treated HIV-infected patients. Parczewski M et al. 2012 AIDS research and human retroviruses
22558263 IFN-λ3 inhibits HIV infection of macrophages through the JAK-STAT pathway. Liu MQ et al. 2012 PloS one
22569080 IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1. Karchava M et al. 2012 European journal of gastroenterology & hepatology
22591106 Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Chen Y et al. 2012 Alimentary pharmacology & therapeutics
22610885 Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Falleti E et al. 2012 Hepatology (Baltimore, Md.)
22613675 Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV. Fiorina L et al. 2012 Journal of virological methods
22626609 Factors that predict response of patients with hepatitis C virus infection to boceprevir. Poordad F et al. 2012 Gastroenterology
22634340 Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. Stättermayer AF et al. 2012 Journal of hepatology
22641049 Genetics of IL28B and HCV--response to infection and treatment. Hayes CN et al. 2012 Nature reviews. Gastroenterology & hepatology
22649509 IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. Shi X et al. 2012 PloS one
22664181 A straightforward genotyping of the relevant IL28B SNPs for the prediction of hepatitis C treatment outcome. Moreira S et al. 2012 Journal of virological methods
22664940 Spontaneous clearance of hepatitis C infection after liver transplantation from IL28B rs12979860 CC donors. Chin JL et al. 2012 European journal of gastroenterology & hepatology
22711348 Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1. Amanzada A et al. 2012 Journal of medical virology
22719902 Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virus. Pedergnana V et al. 2012 PloS one
22727259 Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. Vispo E et al. 2012 Journal of clinical virology
22742526 Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. Schreiber J et al. 2012 Alimentary pharmacology & therapeutics
22754568 Glances in Immunology of HIV and HCV Infection. Quaranta MG et al. 2012 Advances in virology
22766768 The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Duarte-Rojo A et al. 2012 Transplantation
22790387 Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860. Cisneros E et al. 2012 Transplantation
22814458 Targeting both rs12979860 and rs8099917 polymorphisms with a single-tube high-resolution melting assay for IL28b genotyping. Poon KS et al. 2012 Journal of clinical microbiology
22842190 Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis. Shi KQ et al. 2012 Gene
22850127 The genotype frequencies of IL28B polymorphisms (rs12979860, rs8099917) among Turkish patients with hepatitis C. Simsek H et al. 2012 European journal of gastroenterology & hepatology
22863269 Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients. Riva E et al. 2012 Journal of viral hepatitis
22904616 New developments in the management of hepatitis C virus infection: focus on boceprevir. Berenguer M et al. 2012 Biologics
22913807 Genetic polymorphism of IL28B in hepatitis C-infected haemophilia patients in Israel. Maor Y et al. 2013 Haemophilia
22924160 Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin. Jabłonowska E et al. 2012 Acta biochimica Polonica
22930497 IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. Osinusi A et al. 2012 Journal of medical virology
22934000 Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics. Chua EW et al. 2012 Frontiers in pharmacology
22966241 The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. Bellanti F et al. 2012 Clinical & developmental immunology
22992668 Pharmacogenomics knowledge for personalized medicine. Whirl-Carrillo M et al. 2012 Clinical pharmacology and therapeutics
23002361 IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C. Cieśla A et al. 2012 World journal of gastroenterology
23011083 Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. Crespo G et al. 2013 Journal of gastroenterology
23020144 Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy. Shaker OG et al. 2012 Journal of gastroenterology and hepatology
23030669 Interleukin 28B rs12979860 (CT/TT) genotype is associated with milder hepatic damage in the natural evolution of HCV/HIV coinfection. de la Fuente C et al. 2013 Journal of interferon & cytokine research
23032421
23063569 Reply to: "IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients". Petta S et al. 2013 Journal of hepatology
23063570 IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients. Garrett ME et al. 2013 Journal of hepatology
23080496 A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy. Yuan H et al. 2012 Journal of medical virology
23090351 Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1. Jin R et al. 2012 The American journal of gastroenterology
23109451 IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population. Martínez-Gómez LE et al. 2012 Annals of hepatology
23121166 Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. Del Campo JA et al. 2013 Alimentary pharmacology & therapeutics
23121365 IL28B genetic variation and hepatitis C virus-specific CD4(+) T-cell responses in anti-HCV-positive blood donors. Bes M et al. 2012 Journal of viral hepatitis
23133602 Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants. Vidal F et al. 2012 PloS one
23135762 Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. Watanabe T et al. 2013 Gut
23142377 Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis. Luo Y et al. 2013 Gene
23145040 Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients. Rivero-Juárez A et al. 2012 PloS one
23145169 Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy. Claassen MA et al. 2012 PloS one
23159283 Importance of IL-10 and IL-6 during chronic hepatitis C genotype-1 treatment and their relation with IL28B. Pavón-Castillero EJ et al. 2013 Cytokine
23164695 IL28B rs12979860 polymorphism influences serum TNFalpha levels in chronic hepatitis C. Motta BM et al. 2013 Digestive and liver disease
23173032 None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis. Jeng WJ et al. 2012 PloS one
23219017 Cytokines genes polymorphisms in chronic hepatitis C: impact on susceptibility to infection and response to therapy. Pasha HF et al. 2013 Cytokine
23220171 Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. Petta S et al. 2013 Clinical gastroenterology and hepatology
23225905 IL28B single-nucleotide polymorphism rs12979860 is associated with spontaneous HIV control in white subjects. Machmach K et al. 2013 The Journal of infectious diseases
23227209 Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese. Chen J et al. 2012 PloS one
23231085 IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. Antaki N et al. 2013 Journal of viral hepatitis
23238552 Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients. Mandorfer M et al. 2013 AIDS (London, England)
23258530 Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Everhart JE et al. 2013 Hepatology (Baltimore, Md.)
23259930 Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load. Sanabani SS et al. 2012 BMC infectious diseases
23266640 Interleukin-28B rs12979860C/T and rs8099917T/G contribute to spontaneous clearance of hepatitis C virus in Caucasians. Zheng MH et al. 2013 Gene
23268841 Pharmacogenomics of hepatitis C infections: personalizing therapy. Booth DR et al. 2012 Genome medicine
23274935 IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients. Zeremski M et al. 2013 Journal of acquired immune deficiency syndromes (1999)
23284866 Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. Yu ML et al. 2012 PloS one
23291588 A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Prokunina-Olsson L et al. 2013 Nature genetics
23301546 Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. Di Marco V et al. 2013 Journal of viral hepatitis
23301835 IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α. Holmes JA et al. 2013 Journal of gastroenterology and hepatology
23314745 Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. Domagalski K et al. 2013 European journal of clinical microbiology & infectious diseases
23321318 Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. Pol S et al. 2013 Journal of hepatology
23333445 Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. Biggins SW et al. 2013 Journal of hepatology
23383658 HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism. Stenkvist J et al. 2013 Journal of viral hepatitis
23396730 Vitamin D deficiency and vitamin D therapy in chronic hepatitis C. Ladero JM et al. 2013 Annals of hepatology
23439262 A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. Lawitz E et al. 2013 Journal of hepatology
23442843 Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans. Jung YK et al. 2013 Journal of clinical gastroenterology
23449268 HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Seto WK et al. 2013 Clinical infectious diseases
23455512 IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test. Gélinas JF et al. 2013 Immunogenetics
23490377 Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. Piluso A et al. 2013 Journal of viral hepatitis
23490382 Lack of clinical and histological progression of chronic hepatitis C in individuals with true persistently normal ALT: the result of a 17-year follow-up. Nunnari G et al. 2013 Journal of viral hepatitis
23499727 Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. Oliviero B et al. 2013 Journal of hepatology
23522062 IL28B genotype and the expression of ISGs in normal liver. Raglow Z et al. 2013 Liver international
23564545 Interferon-lambda polymorphisms and hepatitis C virus clearance revisited. Lupberger J et al. 2013 Hepatology (Baltimore, Md.)
23587473 Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. Mangia A et al. 2013 Journal of hepatology
23611115 Impact of interleukin 28B polymorphisms on spontaneous clearance of hepatitis C virus infection: a meta-analysis. Yang M et al. 2013 Journal of gastroenterology and hepatology
23611467 CARD8 gene encoding a protein of innate immunity is expressed in human atherosclerosis and associated with markers of inflammation. Paramel GV et al. 2013 Clinical science (London, England
23650587 Using decision tree learning to predict the responsiveness of hepatitis C patients to drug treatment. Kawamura Y et al. 2012 FEBS open bio
23712427 IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. Bibert S et al. 2013 The Journal of experimental medicine
23715768 Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. Di Lello FA et al. 2013 European journal of clinical microbiology & infectious diseases
23722013 Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C. Bitetto D et al. 2013 Digestive and liver disease
23784926 Role of IL28B gene polymorphism and cell-mediated immunity in spontaneous resolution of acute hepatitis C. Spada E et al. 2013 Clinical infectious diseases
23831131 The influence of single and combined IL28B polymorphisms on response to treatment of chronic hepatitis C. Lazarevic I et al. 2013 Journal of clinical virology
23842218 Various predictors of sustained virologic response in different age groups of patients with genotype-1 chronic hepatitis C. Lin CY et al. 2013 Journal of clinical gastroenterology
23850877 Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. Scherzer TM et al. 2013 Journal of hepatology
23850879 Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype. Han H et al. 2013 Journal of hepatology
23855289 Update on epidemiology of hepatitis B and C in China. Cui Y et al. 2013 Journal of gastroenterology and hepatology
23866096 The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients. Derbala M et al. 2013 Virology
23880623 Single-nucleotide polymorphisms of IL-10 and IL-28B as predictors of the response of IFN therapy in HCV genotype 4-infected children. Shaker OG et al. 2013 Journal of pediatric gastroenterology and nutrition
23897630 Clinico-pathological significance of hepatitis C virus core antigen levels in chronic infection. Durante-Mangoni E et al. 2013 Journal of medical virology
23908124 The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Grebely J et al. 2014 Hepatology (Baltimore, Md.)
23919217 Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy. Fujino T et al. 2013 World journal of gastrointestinal pharmacology and therapeutics
23939236 Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C. Krämer B et al. 2013 AIDS (London, England)
23956438 Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. Aka PV et al. 2014 The Journal of infectious diseases
23981065 Association of IL28B polymorphism with fibrosis, liver inflammation, gender respective natural history of hepatitis C virus in Egyptian patients with genotype 4. Youssef SS et al. 2014 Journal of interferon & cytokine research
24039107 Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review. Duarte-Rojo A et al. 2013 Liver transplantation
24057245 Chronic hepatitis B and IL28B rs12979860 polymorphism: preliminary study. Kandemir Ö et al. 2013 Molecular biology reports
24072198 IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. Franco S et al. 2014 AIDS (London, England)
24073221 Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C. García-Martín E et al. 2013 PloS one
24090188 Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. Rao H et al. 2014 Journal of gastroenterology and hepatology
24102823 Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. Ragheb MM et al. 2014 Liver international
24117654 Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b. Tsubota A et al. 2014 Journal of gastroenterology and hepatology
24118626 IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients. Zhang Q et al. 2014 Journal of viral hepatitis
24118647 Hepatitis C virus 5' untranslated region variability correlates with treatment outcome. Bukowska-Ośko I et al. 2014 Journal of viral hepatitis
24118788 Genetic variation in interleukin 28B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients. Al-Qahtani AA et al. 2014 Liver international
24131527 A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers. Real LM et al. 2014 Liver international
24134179 Identification of host and viral factors involved in a dissimilar resolution of a hepatitis C virus infection. Cubero M et al. 2014 Liver international
24144988 Evaluation of the relationship between IL28B, IL10RB and IL28RA single-nucleotide polymorphisms and susceptibility to hepatitis C virus in Chinese Han population. Jin G et al. 2014 Infection, genetics and evolution
24168255 Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy. Liang CM et al. 2013 Journal of viral hepatitis
24168258 Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. Di Marco V et al. 2013 Journal of viral hepatitis
24188401 Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype and modulates gene expression in vivo and in vitro. Rojas Á et al. 2014 Journal of viral hepatitis
24205831 Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Stättermayer AF et al. 2014 Alimentary pharmacology & therapeutics
24219707 Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. Roberts SK et al. 2014 Journal of gastroenterology and hepatology
24224717 Genetic variation in toll-like receptors and retinoic acid-inducible gene I and outcome of hepatitis C virus infection: a candidate gene association study. Clausen LN et al. 2014 Journal of viral hepatitis
24293567 Interleukin 28B gene polymorphisms in hepatitis C virus-related cryoglobulinemic vasculitis. Sansonno D et al. 2014 The Journal of rheumatology
24302757 Natural cytotoxicity receptor-dependent natural killer cytolytic activity directed at hepatitis C Virus (HCV) is associated with liver inflammation, African American race, IL28B genotype, and response to pegylated interferon/ribavirin therapy in chronic HCV infection. Meng Q et al. 2014 The Journal of infectious diseases
24308755 The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. Covolo L et al. 2014 Alimentary pharmacology & therapeutics
24316030 Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. Boglione L et al. 2014 Antiviral research
24329855 Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels. Mandorfer M et al. 2014 Journal of viral hepatitis
24329856 Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection. Mihm U et al. 2014 Journal of viral hepatitis
24342953 Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy. Mandorfer M et al. 2014 Antiviral therapy
24366548 Expression of selected genes in liver biopsy specimens in relation to early virological response in patients with chronic hepatitis C with HCV mono- and HIV/HCV co-infection. Jabłonowska E et al. 2014 Archives of virology
24367041 IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. Meissner EG et al. 2014 The Journal of infectious diseases
24374819 Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. Bravo D et al. 2014 Journal of medical virology
24383923 MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. Jiang M et al. 2014 Journal of viral hepatitis
24387833 No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance. Visco-Comandini U et al. 2014 Digestive and liver disease
24397325 Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C. Keshvari M et al. 2014 Alimentary pharmacology & therapeutics
24397327 Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C--authors' reply. Stättermayer AF et al. 2014 Alimentary pharmacology & therapeutics
24438678 Relationship between polymorphisms near the IL28B gene and spontaneous HBsAg seroclearance: a systematic review and meta-analysis. Lee DH et al. 2014 Journal of viral hepatitis
24445571 Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study. Kamal SM et al. 2014 The American journal of gastroenterology
24462832 Validation of interleukin 28B genotyping assay for clinical use. Cervinski MA et al. 2014 Clinical biochemistry
24516573 Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients. Grammatikos G et al. 2014 PloS one
24517330 Can we include genetic variants with high linkage disequilibrium into a multiple logistic model? Author's reply. Palmieri O et al. 2014 Liver international
24517415 Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B. Wu H et al. 2015 Liver international
24522196 Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. Mancuso ME et al. 2014 Thrombosis and haemostasis
24582569 Effects of polymorphisms in interferon λ 3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection. Yilmaz E et al. 2014 Clinical gastroenterology and hepatology
24602156 Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies. Chen YC et al. 2014 British journal of clinical pharmacology
24620835 Early predictors of antiviral treatment response in liver transplant recipients with recurrent hepatitis C genotype 1. Campos-Varela I et al. 2014 Journal of viral hepatitis
24637774 Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. Sato M et al. 2014 PloS one
24642705 IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis. Liu T et al. 2014 PloS one
24646752 IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population. Ochi H et al. 2014 The Journal of general virology
24654629 Review article: genetic factors that modify the outcome of viral hepatitis. Stättermayer AF et al. 2014 Alimentary pharmacology & therapeutics
24659876 Individualization of chronic hepatitis C treatment according to the host characteristics. Gatselis NK et al. 2014 World journal of gastroenterology
24662995 IL28B polymorphisms and clinical implications for hepatitis C virus infection in Uzbekistan. Khudayberganova D et al. 2014 PloS one
24672032 Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. Estrabaud E et al. 2014 Journal of virology
24681052 Validation of TaqMan® SNP genotyping specificity for rs12979860 of IL-28B: modeling primer specificity in vitro. Thomas BS et al. 2014 Journal of virological methods
24691098 IFN-Alpha receptor-1 upregulation in PBMC from HCV naïve patients carrying cc genotype. possible role of IFN-lambda. Lalle E et al. 2014 PloS one
24696021 Interleukin-28B polymorphisms and response of chronic hepatitis C patients from Indonesia to pegylated interferon/ribavirin treatment. Juniastuti et al. 2014 Journal of clinical microbiology
24707127 Immunologic, metabolic and genetic factors in hepatitis C virus infection. Fierro NA et al. 2014 World journal of gastroenterology
24724563 High-resolution melting assay for genotyping of IFNL4-associated dinucleotide variant rs368234815. Galmozzi E et al. 2014 Clinical microbiology and infection
24726902 Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. Boglione L et al. 2014 Antiviral research
24730732 Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels. Avihingsanon A et al. 2014 Journal of gastroenterology and hepatology
24748394 IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians. Real LM et al. 2014 PloS one
24752012 Hepatic HMOX1 expression positively correlates with Bach-1 and miR-122 in patients with HCV mono and HIV/HCV coinfection. Jabłonowska E et al. 2014 PloS one
24768758 IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Eslam M et al. 2014 Journal of hepatology
24776764 The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. D'Ambrosio R et al. 2014 International journal of molecular sciences
24782280 IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. Akkarathamrongsin S et al. 2014 Journal of medical virology
24812506 Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Liu CH et al. 2014 International journal of nanomedicine
24819603 Involvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C. Tsubota A et al. 2014 PloS one
24840315 Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B. Karataylı SC et al. 2015 Liver international
24841973 Distribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population. Trinks J et al. 2014 The pharmacogenomics journal
24865298 Pharmacogenomics: Current State-of-the-Art. Carr DF et al. 2014 Genes
24874053 Influence of interleukin-28B polymorphism on progression to hepatitis virus-induced hepatocellular carcinoma. He J et al. 2014 Tumour biology
24897020 Genetic variants in human leukocyte antigen-DP influence both hepatitis C virus persistence and hepatitis C virus F protein generation in the Chinese Han population. Xu X et al. 2014 International journal of molecular sciences
24905490 Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection. Laird ME et al. 2014 Journal of hepatology
24914551 Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients. Firdaus R et al. 2014 PloS one
24924923 The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection. Domagalski K et al. 2014 European journal of clinical microbiology & infectious diseases
24927414 Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome. Vidal-Castiñeira JR et al. 2014 PloS one
24946792 Short communication: serum-based assay accurately detects single nucleotide polymorphisms of IL28B and SOCS3 in HIV/hepatitis C virus-coinfected subjects. Shaffer A et al. 2014 AIDS research and human retroviruses
24969847 Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study. Peng CY et al. 2014 BMC gastroenterology
24976707 Human genes involved in hepatitis B virus infection. Zeng Z et al. 2014 World journal of gastroenterology
24994464 Low IL10 serum levels as key factor for predicting the sustained virological response to IFNα/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype. Vasconcelos LR et al. 2014 Human immunology
24996883 Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. Fitzmaurice K et al. 2015 Gut
24999753 Interleukin 28B polymorphisms and therapy response in Egyptian hepatitis C genotype-4 patients. Gouda HM et al. 2014 DNA and cell biology
25013899 Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients. Corchado S et al. 2014 PloS one
25032178 KASL clinical practice guidelines: management of hepatitis C. Korean Association for the Study of the Liver (KASL). et al. 2014 Clinical and molecular hepatology
25032184 No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients. Heo NY et al. 2014 Clinical and molecular hepatology
25059424 Association analysis of polymorphisms in OAS1 with susceptibility and severity of hand, foot and mouth disease. Cai Y et al. 2014 International journal of immunogenetics
25071317 Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children. Indolfi G et al. 2014 World journal of gastroenterology
25098971 Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Guedj J et al. 2014 Hepatology (Baltimore, Md.)
25115611 Is rs8099917 polymorphism of IL-28B gene a good predictor of response to therapy of HCV than rs12979860? An Egyptian study. Shaker O et al. 2015 Cell biochemistry and biophysics
25130512 IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation. Fernández-Carrillo C et al. 2014 Journal of clinical virology
25171028 Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin. Yee BE et al. 2014 European journal of gastroenterology & hepatology
25204264 Not so sweet: autoimmune diabetes mellitus on triple therapy for chronic hepatitis C infection. Blanchard E et al. 2015 Diabetic medicine
25225180 Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: a meta-analysis. Zhang L et al. 2014 Human immunology
25237729 Homozygosity for HLA group 2 alleles predicts treatment failure with interferon-α and ribavirin in chronic hepatitis C virus genotype 1 infection. Collison M et al. 2015 Journal of interferon & cytokine research
25278709 IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. Rosso C et al. 2014 World journal of gastroenterology
25308611 High-dose (peg)interferon therapy in treatment-naïve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C. Orlent H et al. 2015 Digestive and liver disease
25312023 IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population. Dong ZX et al. 2015 Journal of digestive diseases
25332265 The role of interleukin 28B gene polymorphism in Turkish patients with hepatocellular carcinoma. Akkiz H et al. 2014 Annals of hepatology
25343304 Post-transplant course of hepatitis C after living donor liver transplantation in association with polymorphisms near IFNL3. Monaghan KG et al. 2015 Journal of interferon & cytokine research
25349647 Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. Mechie NC et al. 2014 World journal of hepatology
25389973 IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma. Probst M et al. 2014 PloS one
25391769 Frequency of interleukin 28B rs12979860 C>T variants in Filipino patients chronically infected with hepatitis B virus. Baclig MO et al. 2015 Molecular biology reports
25393304 Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. Susser S et al. 2014 PloS one
25429378 Noninvasive characterization of graft steatosis after liver transplantation. Karlas T et al. 2015 Scandinavian journal of gastroenterology
25460552 A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. Chang KC et al. 2015 Clinical gastroenterology and hepatology
25461389 Increased concentration of interferon lambda-3, interferon beta and interleukin-10 in the cerebrospinal fluid of patients with tick-borne encephalitis. Grygorczuk S et al. 2015 Cytokine
25462177 Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. Aziz H et al. 2015 International journal of infectious diseases
25504078 Host genetics predict clinical deterioration in HCV-related cirrhosis. King LY et al. 2014 PloS one
25580520 Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. Hajarizadeh B et al. 2015 Journal of viral hepatitis
25587543 T-cell cytokine gene polymorphisms and vitamin D pathway gene polymorphisms in end-stage renal disease due to type 2 diabetes mellitus nephropathy: comparisons with health status and other main causes of end-stage renal disease. Grzegorzewska AE et al. 2014 Journal of diabetes research
25611696 Impaired induction of interleukin 28B and expression of interferon λ 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C. Murakawa M et al. 2015 Journal of gastroenterology and hepatology
25639146 Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. Wong GL et al. 2015 Journal of gastroenterology and hepatology
25652367 IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C. Shaikh N et al. 2015 Journal of medical virology
25660111 Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage. Boglione L et al. 2015 Antiviral research
25664396 Gene polymorphisms of interleukin 28B and the risk to chronic hepatitis B virus infection in Thai. Kimkong I et al. 2015 Tissue antigens
25668821 Interferon lambda-3 polymorphism and response to pegylated interferon in patients with hepatitis D. Abbas Z et al. 2015 Antiviral therapy
25687192 Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms. Ling Q et al. 2015 Archives of virology
25703417 Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population. Imran M et al. 2015 APMIS
25705565 Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals. Sehgal M et al. 2014 Journal of clinical & cellular immunology
25708904 The genotype CC of IL-28B SNP rs12979860 is significantly associated with a sustained virological response in chronic HCV-infected Pakistani patients. Khubaib B et al. 2015 Journal of digestive diseases
25712648 IL28B polymorphism (rs12979860) associated with clearance of HCV infection in Poland: systematic review of its prevalence in chronic hepatitis C patients and general population frequency. Kaczor MP et al. 2015 Pharmacological reports
25747035 Genetic variations of IL-28B and PD-1 are in association with the susceptibility and outcomes of HCV infection in Southeast China. Xiao W et al. 2015 Infection, genetics and evolution
25769643 IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis. Zheng H et al. 2015 Clinics and research in hepatology and gastroenterology
25777542 Association between individual and combined SNPs in genes related to innate immunity and incidence of CMV infection in seropositive kidney transplant recipients. Fernández-Ruiz M et al. 2015 American journal of transplantation
25803108 Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals. Moqueet N et al. 2015 International journal of molecular sciences
25818002 Association between IL28B polymorphism, TNFα and biomarkers of insulin resistance in chronic hepatitis C-related insulin resistance. Lemoine M et al. 2015 Journal of viral hepatitis
25836019 Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. Cusato J et al. 2015 International journal of antimicrobial agents
25837166 IL28B is associated with outcomes of chronic HBV infection. Shi X et al. 2015 Yonsei medical journal
25844942 IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C. Estrabaud E et al. 2015 PloS one
25852288 Interferon-λ-related genes and therapeutic response in Chinese hepatitis C patients. Zhang YY et al. 2015 World journal of gastroenterology
25863261 Comparison of four methods of genotyping IL28B polymorphisms in chronic hepatitis C patients. Delvaux N et al. 2015 Journal of virological methods
25864220 IFNL3 polymorphisms and HCV infection in patients with beta thalassemia. Origa R et al. 2015 Annals of hepatology
25883387 Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study. Sacks-Davis R et al. 2015 The Journal of infectious diseases
25918016 Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. Cariani E et al. 2016 The pharmacogenomics journal
25936570 Potential genetic markers for prediction of treatment response in Egyptian children infected with HCV genotype 4. Rady NH et al. 2015 Cytokine
25938236 Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection. Thong VD et al. 2015 PloS one
25942723 Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. Poordad F et al. 2015 JAMA
25958342 The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C. Nadia K et al. 2015 Gene
25962810 A meta-analysis of the association between IL28B polymorphisms and infection susceptibility of hepatitis B virus in Asian population. Chen J et al. 2015 BMC gastroenterology
25970604 IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors. Olmedo DB et al. 2015 Journal of medical virology
25971683 Differential distribution of IL28B.rs12979860 single-nucleotide polymorphism among Egyptian healthcare workers with and without a hepatitis C virus-specific cellular immune response. Abdelwahab SF et al. 2015 Archives of virology
26020282 Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study. Noureddin M et al. 2015 Genes and immunity
26032235 The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3. Holmes JA et al. 2015 Alimentary pharmacology & therapeutics
26034208 Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. Rogalska-Taranta M et al. 2015 Journal of leukocyte biology
26060059 Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. Boglione L et al. 2015 Archives of virology
26079279 HCV F protein amplifies the predictions of IL-28B and CTLA-4 polymorphisms about the susceptibility and outcomes of HCV infection in Southeast China. Xiao W et al. 2015 Infection, genetics and evolution
26086432 High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with Chronic Hepatitis C; A Case-Control Study. Mehrnoush L et al. 2015 Pediatric hematology and oncology
26098993 Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. Doyle JS et al. 2015 Journal of viral hepatitis
26115415 The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C. Domagalski K et al. 2015 PloS one
26115445 Association of IFNL3 and IFNL4 polymorphisms with liver-related mortality in a multiracial cohort of HIV/HCV-coinfected women. Sarkar M et al. 2015 Journal of viral hepatitis
26147900 Interleukin-28B polymorphisms and interferon gamma inducible protein-10 serum levels in seronegative occult hepatitis C virus infection. Bartolomé J et al. 2016 Journal of medical virology
26150150 Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types. Lamoury FM et al. 2015 The Journal of molecular diagnostics
26156685 Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients. Dzekova-Vidimliski P et al. 2015 Renal failure
26175521 Spontaneous Clearance of the Hepatitis C Virus Among Men Who Have Sex With Men. Seaberg EC et al. 2015 Clinical infectious diseases
26177560 Interleukin- 28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response. Resham S et al. 2015 APMIS
26186989 Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. O'Brien TR et al. 2015 Journal of hepatology
26189761 A genetic variant in the interleukin 28B gene as a major predictor for sustained virologic response in chronic hepatitis C virus infection. Sixtos-Alonso MS et al. 2015 Archives of medical research
26191484 IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. Calisti G et al. 2015 SpringerPlus
26209404 Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population. Sghaier I et al. 2015 Journal of clinical virology
26259026 TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. Petta S et al. 2016 Liver international
26263394 Prevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of Nepal. Kinkel HT et al. 2015 PloS one
26269684 Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. Haj-Sheykholeslami A et al. 2015 World journal of gastroenterology
26280154 Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients. Esmail MA et al. 2016 Journal of medical virology
26280523 Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection. Abdelwahab SF et al. 2015 Archives of virology
26284539 Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C. Schwarz KB et al. 2016 Journal of pediatric gastroenterology and nutrition
26313459 Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response. Read SA et al. 2015 PloS one
26334898 Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins. Bellanti F et al. 2015 Medicine
26339796 Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection. Thanapirom K et al. 2015 PloS one
26376789 Association of interferon-gamma inducible protein 10 polymorphism with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B. Limothai U et al. 2016 Antiviral therapy
26378651 Polymorphisms in EGFR and IL28B are associated with spontaneous clearance in an HCV-infected Iranian population. Carapito R et al. 2015 Genes and immunity
26381047 The interaction of genetic determinants in the outcome of HCV infection: evidence for discrete immunological pathways. Hydes TJ et al. 2015 Tissue antigens
26387494 A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response. Tangkijvanich P et al. 2016 Journal of viral hepatitis
26389885 Duplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C Patients. Enache EL et al. 2015 International journal of molecular sciences
26394672 Association of Single-Nucleotide Polymorphisms in IL28B, but Not TNF-α, With Severity of Disease Caused by Andes Virus. Angulo J et al. 2015 Clinical infectious diseases
26403160 Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study. Hayashi N et al. 2016 Journal of gastroenterology
26406534 Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. Peiffer KH et al. 2016 Hepatology (Baltimore, Md.)
26418670 Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. Waldenström J et al. 2016 Scandinavian journal of gastroenterology
26420957 Chronic hepatitis C virus infection and lipoprotein metabolism. Aizawa Y et al. 2015 World journal of gastroenterology
26431156 Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes. Lang Kuhs KA et al. 2015 PloS one
26468348 Distribution of IL-28B genotypes in patients with hepatitis C and healthy individuals in Jahrom city. Mousavi Nasab SD et al. 2015 Gastroenterology and hepatology from bed to bench
26470765 Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China. Zhang R et al. 2016 Gut and liver
26485009 Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients. Sticchi L et al. 2015 The new microbiologica
26546777 IL28B gene polymorphisms and Th1/Th2 cytokine levels might be associated with HTLV-associated arthropathy. de Sá KS et al. 2016 Cytokine
26556986 Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico. Ramos-Lopez O et al. 2015 World journal of gastroenterology
26563120 Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Sarin SK et al. 2016 Hepatology international
26599080 The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. Scheiner B et al. 2015 PloS one
26602024 Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. Lee MH et al. 2015 Scientific reports
26650626 ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. Asselah T et al. 2015 PloS one
26670100 Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. About F et al. 2015 PloS one
26676813 Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease. Kahali B et al. 2015 Seminars in liver disease
26699619 Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. Wiegand SB et al. 2015 PloS one
26741362 Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from Mexico. Gonzalez-Aldaco K et al. 2016 PloS one
26743840 Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Johnson DC et al. 2016 Nature communications
26789637 Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals. Nguyen LT et al. 2016 Antiviral therapy
26820907 IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection. Wu R et al. 2016 Infection, genetics and evolution
26848682 Genetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV Infections. Assone T et al. 2016 Viruses
26854475 Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. Mueller JL et al. 2016 Clinical transplantation
26896692 Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression. Ferraris P et al. 2016 The American journal of pathology
26902034 Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4. El-Bendary M et al. 2015 Hepato-gastroenterology
26911666 Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C. El-Derany MO et al. 2016 BMC gastroenterology
26912610 Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection. Swann RE et al. 2016 Journal of virology
26933517 Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus. Wu LS et al. 2016 CPT
26945900 Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a. Pedergnana V et al. 2016 Hepatology (Baltimore, Md.)
26946328 Reply. Peiffer KH et al. 2016 Hepatology (Baltimore, Md.)
26954674 Alteration of Antiviral Signalling by Single Nucleotide Polymorphisms (SNPs) of Mitochondrial Antiviral Signalling Protein (MAVS). Xing F et al. 2016 PloS one
26962819 GC Gene Polymorphism and Unbound Serum Retinol-Binding Protein 4 Are Related to the Risk of Insulin Resistance in Patients With Chronic Hepatitis C: A Prospective Cross-Sectional Study. Mateos-Muñoz B et al. 2016 Medicine
26973228 Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil. de Seixas Santos Nastri AC et al. 2016 Archives of virology
26984148 Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection. Moqueet N et al. 2016 The Journal of infectious diseases
26986131 Human Cytokine Genetic Variants Associated With HBsAg Reverse Seroconversion in Rituximab-Treated Non-Hodgkin Lymphoma Patients. Hsiao LT et al. 2016 Medicine
27010195 Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis. Thong VD et al. 2015 Intervirology
27012446 Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication? Di Marco V et al. 2016 Digestive and liver disease
27022224 Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. Jacobson I et al. 2016 World journal of gastroenterology
27035616 Interferon lambda and hepatitis C virus core protein polymorphisms associated with liver cancer. Moreira JP et al. 2016 Virology
27047769 Association of Overt Diabetes Mellitus with the Non-CC but not the CC Genotype of Interleukin-28B in Hepatitis C Virus Infected Patients. Kumar A et al. 2016 Journal of clinical and translational hepatology
27063552 C7 genotype of the donor may predict early bacterial infection after liver transplantation. Zhong L et al. 2016 Scientific reports
27083168 Interleukin-28B TT genotype is frequently found in patients with hepatitis C virus cirrhosis but does not influence hepatocarcinogenesis. de la Fuente S et al. 2017 Clinical and experimental medicine
27100663 Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4. Rizk HH et al. 2016 PloS one
27135246 Transcriptional Dysregulation of Upstream Signaling of IFN Pathway in Chronic HCV Type 4 Induced Liver Fibrosis. Ibrahim MK et al. 2016 PloS one
27139837 Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia. Cusato J et al. 2016 Pharmacogenetics and genomics
27148387 The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C. Pouryasin M et al. 2016 Hepatitis monthly
27172242 Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers. Romagnoli R et al. 2016 Transplant international
27196570 Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection. Fischer J et al. 2017 Gut
27226800 The Correlation Between Interferon Lambda 3 Gene Polymorphisms and Susceptibility to Hepatitis B Virus Infection. Heidari Z et al. 2016 Hepatitis monthly
27236152  Association of HLA-DQ and IFNL4 polymorphisms with susceptibility to hepatitis B virus infection and clearance. Fan JH et al. 2016 Annals of hepatology
27275739 Association of IL28B SNPs rs12979860 and rs8099917 on Hepatitis C Virus-RNA Status in Donors/Recipients of Living Donor Liver Transplantation. Chiu KW et al. 2016 PloS one
27304910 A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. Huik K et al. 2016 PloS one
27313470 Meta-analysis of associations of interleukin-28B polymorphisms rs8099917 and rs12979860 with development of hepatitis virus-related hepatocellular carcinoma. Zhang Y et al. 2016 OncoTargets and therapy
27340680 Genetic Variation in the IL-6 and HLA-DQB1 Genes Is Associated with Spontaneous Clearance of Hepatitis C Virus Infection. Waldron PR et al. 2016 Journal of immunology research
27346846 Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type. Fülöp B et al. 2016 Journal of viral hepatitis
27366029 Vitamin D deficiency in patients with liver cirrhosis. Konstantakis C et al. 2016 Annals of gastroenterology
27371869 Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients. Langman LJ et al. 2016 The Journal of molecular diagnostics
27459258
27477870 Resistin reinforces interferon λ-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotide polymorphisms. Chang ML et al. 2016 Scientific reports
27498543 Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3? Mansoor S et al. 2016 The Journal of general virology
27544760 Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. Mehta M et al. 2016 Archives of virology
27547017 Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. Severson TJ et al. 2016 World journal of gastroenterology
27591738 IL28B genetic variation and cytomegalovirus-specific T-cell immunity in allogeneic stem cell transplant recipients. Corrales I et al. 2017 Journal of medical virology
27595449 Antibodies to HBV surface antigen in relation to interferon-λ3 in hemodialysis patients. Grzegorzewska AE et al. 2016 Vaccine
27601657 Influence of IFNL3 and HLA-DPB1 genotype on postpartum control of hepatitis C virus replication and T-cell recovery. Honegger JR et al. 2016 Proceedings of the National Academy of Sciences of the United States of America
27601663 Prolonged activation of innate antiviral gene signature after childbirth is determined by IFNL3 genotype. Price AA et al. 2016 Proceedings of the National Academy of Sciences of the United States of America
27630043 MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Thabet K et al. 2016 Nature communications
27642141 Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells. Klepper A et al. 2017 Hepatology (Baltimore, Md.)
27656234 The Role of Interferon Lambda 3 Genetic Polymorphisms in Response to Interferon Therapy in Chronic Hepatitis B Patients: An Updated Meta-Analysis. Lin Z et al. 2016 Hepatitis monthly
27660680 Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective. Afzal MS et al. 2016 World journal of hepatology
27726464 Three Gene Signature for Predicting the Development of Hepatocellular Carcinoma in Chronically Infected Hepatitis C Virus Patients. Ibrahim MK et al. 2016 Journal of interferon & cytokine research
27729747 Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C. Sultana C et al. 2016 World journal of gastroenterology
27733412 Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional study. Yan LB et al. 2016 BMJ open
27812403 The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia. Bogdanović Z et al. 2016 PeerJ
27870883 Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity. Chang ML et al. 2016 PloS one
27895405 Impact of IL28B and <i>OAS</i> gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus. Domagalski K et al. 2016 World journal of gastroenterology
27917361 <i>IL28B</i> genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. Mangia A et al. 2016 SpringerPlus
27917597 Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia. Durier N et al. 2017 Journal of viral hepatitis
27925355 Epigenetic analysis of the IFNλ3 gene identifies a novel marker for response to therapy in HCV-infected subjects. Waring JF et al. 2017 Journal of viral hepatitis
27998720 Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment. Huang CF et al. 2017 EBioMedicine
28036111 Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients. Murakawa M et al. 2017 Journal of medical virology
28058039 Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients. Palenzuela Gardón D et al. 2017 Journal of biomolecular techniques
28070198 Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. Almasio PL et al. 2016 Hepatitis monthly
28141591 Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta. Ispiroglu M et al. 2017 Journal of infection in developing countries
28144454 Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C. Daneshvar M et al. 2016 Iranian Red Crescent medical journal
28186161 Genetic variants in interferon-λ 4 influences HCV clearance in Chinese Han population. Huang P et al. 2017 Scientific reports
28211229 Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients. Shaker OG et al. 2017 Journal of viral hepatitis
28211910 Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance. Chang ML et al. 2017 Scientific reports
28214926 Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. Alborzi A et al. 2017 Medical microbiology and immunology
28224025 Lack of association between interleukin 28B gene polymorphisms (rs8099917G/T, rs12979860 C/T) and susceptibility to chronic hepatitis C virus infection, Tehran, Iran. Karkhane M et al. 2016 Gastroenterology and hepatology from bed to bench
28253210 The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study. Uygun A et al. 2017 European journal of gastroenterology & hepatology
28281380 A comparative study of various methods for detection of IL28B rs12979860 in chronic hepatitis C. Monavari SH et al. 2017 Scandinavian journal of clinical and laboratory investigation
28299025 Interleukin-28B rs12979860 C/T Polymorphism and Acute Cellular Rejection after Liver Transplantation. Fereidooni H et al. 2017 International journal of organ transplantation medicine
28315743 Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. Boglione L et al. 2017 Infection, genetics and evolution
28335783 SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China. Li Y et al. 2017 Virology journal
28394349 IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Eslam M et al. 2017 Nature genetics
28419488 Interferon λ3 gene (IL28B) is associated with spontaneous or treatment-induced viral clearance in hepatitis C virus-infected multitransfused patients with thalassemia. Biswas A et al. 2017 Transfusion
28440692 Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C. Benito JM et al. 2017 Journal of interferon & cytokine research
28453396 Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. Cusato J et al. 2017 Pharmacogenomics
28502145 Study of Interleukin 28B rs12979860 and rs8099917 Polymorphisms and T-helper 1 Response in Hepatitis C Virus Patients. Ea R et al. 2015 The Egyptian journal of immunology
28513591 Zinc is a potent and specific inhibitor of IFN-λ3 signalling. Read SA et al. 2017 Nature communications
28579527 Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C. Boglione L et al. 2017 Infection, genetics and evolution
28608576 Evaluation of three techniques for detection of IL28B SNP: A prognostic tool for HCV treatment outcome. Khubaib B et al. 2017 Journal of digestive diseases
28614389 Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C. Lee JW et al. 2017 PloS one
28638221 Prevalence of <i>IFNL3</i> rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C. Świątek-Kościelna B et al. 2017 World journal of gastroenterology
28655358 The association between interleukin-28B gene polymorphisms as a potential biomarker and the risk of chronic Periodontitis in an Iranian population. Heidari Z et al. 2017 Head & face medicine
28681817 The evaluation of interferon lambda 4 rs368234815 as a predictor factor in treated patients with chronic hepatitis C genotype 1a infection. Jalilian S et al. 2017 Indian journal of medical microbiology
28703131 EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. Asnavandi M et al. 2017 Genes and immunity
28704535 Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C. López-Rodríguez R et al. 2017 PloS one
28723780 The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients. Liu Z et al. 2017 Medicine
28739427 The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection. Sakhaee F et al. 2017 Infection, genetics and evolution
28741298 Interferon lambda 4 rs368234815 TT&gt;δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Petta S et al. 2017 Hepatology (Baltimore, Md.)
28751760 IL28B rs12979860 genotype as a predictor marker of progression to BKVirus Associated nephropathy, after kidney transplantation. Dvir R et al. 2017 Scientific reports
28797039 Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. Huang CM et al. 2017 PloS one
28820758 Lack of Association Between Interleukin 28B Polymorphism and Vertical Transmission of Hepatitis C. Psaros Einberg A et al. 2017 Journal of pediatric gastroenterology and nutrition
28834572 Multiple genetic variants associated with posttransplantation diabetes mellitus in Chinese Han populations. Chen J et al. 2018 Journal of clinical laboratory analysis
28856250 Impact of rs12979860 polymorphism on liver morphology in chronic HCV infection. Łapiński TW et al. 2015 Clinical and experimental hepatology
28860020 Triplex High-Resolution Melting Assay for the Simultaneous Assessment of IFNL3 rs12979860, ABCB11 rs2287622, and RNF7 rs16851720 Genotypes in Chronic Hepatitis C Patients. Enache EL et al. 2017 The Journal of molecular diagnostics
28874741 A functional IFN-λ4-generating DNA polymorphism could protect older asthmatic women from aeroallergen sensitization and associate with clinical features of asthma. Chinnaswamy S et al. 2017 Scientific reports
28877177 An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms. Duffy D et al. 2017 PloS one
28894041 Analysis of the relationship between single nucleotide polymorphism of the CD209, IL-10, IL-28 and CCR5 D32 genes with the human predisposition to developing tick-borne encephalitis. Czupryna P et al. 2017 Postepy higieny i medycyny doswiadczalnej (Online)
28903504 Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele. Hashem M et al. 2017 Clinical infectious diseases
28984602 Modulation of Immune Responses to Herpes Simplex Virus Type 1 by IFNL3 and IRF7 Polymorphisms: A Study in Alzheimer's Disease. Costa AS et al. 2017 Journal of Alzheimer's disease
29022122 Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. Nguyen LT et al. 2018 Archives of virology
29040985 Serum IFN-λ3 Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis C. Imoto S et al. 2017 Digestive diseases (Basel, Switzerland)
29055988 [Association of HLA-DQ and IFNL4 polymorphisms with hepatitis B virus infection and clearance]. Chen H et al. 2017 Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
29062905 The impact of the recipient and donor interferon lambda-3 polymorphism on the course of HCV infection following liver transplantation. Wieczorek-Godlewska R et al. 2017 Clinical and experimental hepatology
29080719 Interleukin 28B rs12979860 genotype and Human Immunodeficiency Virus type 1: Susceptibility, AIDS development and therapeutic outcome. Zaidane I et al. 2018 Human immunology
29095252 Association of interleukin-28B polymorphisms with platelet count and liver function recovery after liver transplant. Li Y et al. 2017 Medicine
29130827 Association of Single-Nucleotide Polymorphisms in Immune-Related Genes with Development of Dengue Hemorrhagic Fever in a Mexican Population. Vargas-Castillo AB et al. 2018 Viral immunology
29193749 Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years. Borobia AM et al. 2018 Clinical and translational science
29210660 Host Factor Predictors in Long-term Nonprogressors HIV-1 Infected with Distinct Viral Clades. Dos Santos JS et al. 2017 Current HIV research
29226133 Circulating Interferon-<i>λ</i>3, Responsiveness to HBV Vaccination, and HBV/HCV Infections in Haemodialysis Patients. Grzegorzewska AE et al. 2017 BioMed research international
29254684 Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy. Chang KC et al. 2018 Journal of the Formosan Medical Association = Taiwan yi zhi
29264884 Distribution of polymorphisms rs12979860, rs8099917 and rs12980275 IL28B in patients with chronic hepatitis C. Wysocka-Leszczyńska J et al. 2017 Advances in clinical and experimental medicine
29279441 Data Mining and Machine Learning Algorithms Using IL28B Genotype and Biochemical Markers Best Predicted Advanced Liver Fibrosis in Chronic Hepatitis C. Shousha HI et al. 2018 Japanese journal of infectious diseases
29284412 CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV. Lin CC et al. 2017 BMC gastroenterology
29302390 Association between genetic polymorphisms of the <i>IL28B</i> gene and leukomonocyte in Chinese hepatitis B virus-infected individuals. Song Y et al. 2017 PeerJ
29340806 Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients. Naeemi H et al. 2018 Archives of virology
29369421 Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms. Lindgren M et al. 2018 European journal of haematology
29399747 Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C. Zhu DY et al. 2018 Archives of virology
29404438 A global perspective on hepatitis B-related single nucleotide polymorphisms and evolution during human migration. Tai DI et al. 2017 Hepatology communications
29405153 Effect of Interleukin-28B polymorphism on Interleukin-28 expression and immunological recovery amongst HIV-1-infected individuals following antiretroviral therapy. Srinidhi BV et al. 2017 Indian journal of medical microbiology
29429413 A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan. Zia A et al. 2018 Infectious diseases of poverty
29488481 [Predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis C virus genotype 1]. Kokina KY et al. 2017 Terapevticheskii arkhiv
29499724 IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients. Echeverría N et al. 2018 Virology journal
29510558 Helicobacter Pylori Serology in Relation to Hepatitis C Virus Infection and IL28B Single Nucleotide Polymorphism. Gutwerk A et al. 2018 Journal of clinical medicine
29562888 IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes. Egli A et al. 2018 BMC pulmonary medicine
29605690 Lack of evidence of association between IFNG and IL28B polymorphisms and QuantiFERON-CMV test results in seropositive transplant patients. Aguado R et al. 2018 Human immunology
29664710 Analysis of Host and Viral-Related Factors Associated to Direct Acting Antiviral Response in Hepatitis C Virus Patients. Aziz H et al. 2018 Viral immunology
29666343 Interleukin gene polymorphisms and susceptibility to HIV-1 infection: a meta-analysis. Tsiara CG et al. 2018 Journal of genetics
29686997 Identification of IL-28B Genotype Modification in Hepatocytes after Living Donor Liver Transplantation by Laser Capture Microdissection and Pyrosequencing Analysis. Chiu KW et al. 2018 BioMed research international
29739095 Distribution of IL28B rs12979860 and rs8099917 Genotypes in Patients with Chronic Hepatitis C Virus Infection in Tianjin, China. Qiao K et al. 2018 Clinical laboratory
29853737 Regulatory polymorphism of CXCL10 rs1439490 in seronegative occult hepatitis C virus infection. Wang X et al. 2018 World journal of gastroenterology
29866105 Polymorphisms in the Th17 cell-related RORC gene are associated with spontaneous clearance of HCV in Chinese women. Xie Z et al. 2018 BMC infectious diseases
29888255 Hepatitis C Virus-Infected Responders and Relapsers to Treatment Show Similar Genetic Profiles of <i>IL28B</i> and <i>IL10</i> Single Nucleotide Polymorphisms. de Souza SL et al. 2018 BioMed research international
29893697 Extracellular Matrix Proteins Substantiate IL-28B T allele Effect on Histological Outcome of Chronic Hepatitis C. Attallah AM et al. 2018 Annals of hepatology
29910570 The Role of Biochemical Variations and Genotype Testing in Determining the Virological Response of Patients Infected with Hepatitis C Virus. Shoukat A et al. 2018 Journal of global infectious diseases
29914308 IL-28B rs12979860 polymorphism affect the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4. Attallah AM et al. 2018 British journal of biomedical science
29935858 Correlations of indoleamine 2,3-dioxygenase, interferon-λ3, and anti-HBs antibodies in hemodialysis patients. Grzegorzewska AE et al. 2018 Vaccine
29992584 Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. Jõgeda EL et al. 2018 Journal of medical virology
30011346 High spontaneous clearance of symptomatic iatrogenic acute hepatitis C genotype 4 infection. Hashem M et al. 2018 Journal of medical virology
30016335 No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. Wei L et al. 2018 PloS one
30027841 Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses. Grzegorzewska AE et al. 2018 Current medicinal chemistry
30036376 Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients. Annibali O et al. 2018 PloS one
30077763 IL28B, IL29 and micro-RNA 548 in subacute sclerosing panencephalitis as a rare disease. Cakmak Genc G et al. 2018 Gene

Genomic regions, transcripts, and products
Top Help

NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.

Software version is: 2.0.1.post76+b4aec9c